Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018, 162(2):154-158 | DOI: 10.5507/bp.2017.044

Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Schönlein purpura

Jana Volejnikovaa, Jaroslav Horacekb, Frantisek Koprivaa
a Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
b Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic

Background: Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and by the deposition of IgA immune complexes. An association between HSP and atypical bacteria is uncommon in children.

Methods and Results: Here we report three cases of children, aged 5, 4 and 16 years, who were diagnosed with HSP associated with Mycoplasma pneumoniae or Chlamydia pneumoniae infection. In all presented cases, persistent cutaneous manifestations and abdominal pain were resistant to antibiotics and corticosteroids, but resolved during 48 h after the introduction of dapsone. No adverse effects of treatment were observed.

Conclusion: Dapsone, a sulphone with an anti-inflammatory activity, showed remarkable therapeutic efficacy against rash and gastrointestinal symptoms in children with HSP. Its administration should be considered particularly in persistent cutaneous form of HSP.

Keywords: atypical bacteria, children, Henoch-Schönlein purpura, dapsone

Received: May 29, 2017; Accepted: October 6, 2017; Prepublished online: November 2, 2017; Published: June 25, 2018  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Volejnikova, J., Horacek, J., & Kopriva, F. (2018). Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Schönlein purpura. Biomedical papers, 162(2), 154-158. doi: 10.5507/bp.2017.044
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Roberts PF, Waller TA, Brinker TM, Riffe IZ, Sayre JW, Bratton RL. Henoch-Schönlein purpura: a review article. South Med J 2007;100(8):821-4. Go to original source... Go to PubMed...
    2. Calvo-Rio V, Hernandes JL, Ortiz-Sanjuan F, Loricera J, Palmou-Fontana N, González-Vela MC, González-Lamuño D, González-López MA, Armesto S, Blanco R, González-Gay MA. Relapses in patients with Henoch-Schönlein purpura: Analysis of 417 patients from a single center. Medicine (Baltimore) 2016;95(28):e4217. Go to original source... Go to PubMed...
    3. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999;78(6):395-409. Go to original source... Go to PubMed...
    4. Ledermann JA, Hoffbrand BI. Dapsone in allergic vasculitis: its use in Henoch-Schönlein disease following vaccination. J R Soc Med 1983;76(7):613-4. Go to original source... Go to PubMed...
    5. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987;16(4):772-8. Go to original source... Go to PubMed...
    6. Iqbal H, Evans A. Dapsone therapy for Henoch-Schonlein purpura: a case series. Arch Dis Child 2005;90(9):985-6. Go to original source... Go to PubMed...
    7. Shin JI, Lee JS, Chung KS. Dapsone therapy for Henoch-Schonlein purpura. Arch Dis Child 2006;91(8):714.
    8. Papandreou T, Dürken M, Goebeler M, Hoeger PH, Goerdt S, Peitsch WK. Chronic recalcitrant Henoch-Schönlein purpura: successful treatment with dapsone. Eur J Dermatol 2010;20(5):639-40.
    9. Mazille N, Lipsker D, Fischbach M. Dapsone for chronic skin lesions in 3 children suffering from Henoch-Schönlein vasculitis. Arch Pediatr 2011;18(11):1201-4. Go to original source... Go to PubMed...
    10. Bech AP, Reichert LJ, Cohen Tervaert JW. Dapsone for the treatment of chronic IgA vasculitis (Henoch-Schonlein). Neth J Med 2013;71(4):220-1.
    11. Jayavardhana A, Vijayalakshmi AM. Dapsone hypersensitivity syndrome during Henoch-Schonlein purpura treatment. Indian Dermatol Online J 2014;5:93-4. Go to original source... Go to PubMed...
    12. Chen CB, Garlapati S, Lancaster JD, Zinn Z, Bacaj P, Patra KP. Bullous Henoch-Schönlein purpura in children. Cutis 2015;96(4):248-52. Go to PubMed...
    13. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990;33(8):1114-21. Go to original source...
    14. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P. EULAR/PreS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65(7):936-41. Go to original source... Go to PubMed...
    15. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69(5):798-806.
    16. Ortiz-Sanjuan F, Blanco R, Hernandez JL, González-López MA, Loricera J, Lacalle-Calderón M, Pina T, Calvo-Río V, Álvarez L, González-Vela MC, Rueda-Gotor J, González-Gay MA. Applicability of the 2006 European League Against Rheumatism (EULAR) criteria for the classification of Henoch-Schönlein purpura. An analysis based on 766 patients with cutaneous vasculitis. Clin Exp Rheumatol 2015;33(2 Suppl 89):S44-7.
    17. Beltran Garcia S, Dominiquez Cajal M, Lafuente Hidalgo M García Sánchez N, Benito Ruesca R. Henoch-Schönlein purpura and Chlamydophila pneumoniae. An Pediatr 2008;68(2):196-7. Go to original source...
    18. Ku¼ma-Mroczkowska E, Pañczyk-Tomaszewska M, Szmigielska A, Szymanik-Grzelak H, Roszkowska-Blaim M. Mycoplasma pneumoniae as a trigger for Henoch-Schönlein purpura in children. Cent Eur J Immunol 2015;40(4):489-92. Go to original source... Go to PubMed...
    19. Terraneo L, Lava SA, Camozzi P, Zgraggen L, Simonetti GD, Bianchetti MG, Milani GP. Unusual Eruptions Associated with Mycoplasma pneumoniae Respiratory Infections: Review of the Literature. Dermatology 2015;231(2):152-7. Go to original source... Go to PubMed...
    20. Ford PG. Dapsone. Curr Probl Dermatol 2000;12(5):242-5. Go to original source...
    21. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45(3):420-34. Go to original source... Go to PubMed...

    Return to the content